Method for producing vascularized heart organoid through co-differentiation of pluripotent stem cells
By introducing Tet 3G and ETV2 genes into iPSCs and inducing ETV2 expression with doxycycline to promote endothelial cell network formation, the problem of expensive growth factor dependence in existing cardiac organoid construction is solved, realizing a simple and reproducible vascularization method for cardiac organoids and improving the physiological relevance and functionality of organoids.
Patent Information
- Application Number
- CN202610330585.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-18
- Publication Date
- 2026-05-29
AI Technical Summary
In existing methods for constructing cardiac organoids, the co-development of endothelial cells and cardiomyocytes depends on the expensive growth factor VEGF-A, which is complex to operate and not applicable to various construction methods. There is also a lack of simple and reproducible vascularization methods.
Using a pluripotent stem cell co-differentiation method, exogenous genes Tet 3G and ETV2 were introduced into iPSCs. Doxycycline was used to induce ETV2 expression, which promoted the formation of endothelial cell networks and replaced the role of VEGF-A, thereby achieving vascularization of cardiac organoids.
It enables the co-development of endothelial cells and cardiomyocytes, avoids the use of expensive growth factors, simplifies the operation process, is applicable to various cardiac organoid construction methods, and improves the physiological relevance and functional maturity of organoids.